From the finest Medical University  in Korea  To leading international medical research center
01 S N U C M
G
02
C O N T E N T S •Dean’s Message
04 – 05
•History of Seoul National University College of Medicine
06 – 13
•Part 1. Education and Research
14 – 29
Education
16
Research
24
Campus Life
28
•Part 2. Connection and Expansion
30 – 45
Lee Jong Wook – Seoul Project
32
JW LEE Center for Global Medicine
34
Institute for Health and Unification Studies
36
International Partnerships
40
Alumni
42
Training Hospitals
44
Dean's Message
4
Seoul National University College of Medicine Aiming High for World-class Seoul National University College of Medicine boasts 520 dedicated professors who have an outstanding reputation for excellence in teaching and medical research. With over 2,000 students in undergraduate and graduate programs, we offer the exceptional education and training under the mission of nurturing competent health care providers and scientists. I have the utmost confidence that graduates of our college will play a pivotal role in health care and medical research not just in Korea but also across the world in the future. After finishing two-year Premedical course, students are provided with in-depth knowledge and scientific understanding of diseases, in addition to vital interpersonal communication skills to engage with patients at the College of Medicine for 4 years. We also offer a wide range of disciplines of more than 50’s master’s and doctoral programs in biomedical research to help students reach their career goals. Our faculty is devoted to providing the highest standard of medical treatment and research in all fields of medical science as well as the public contribution to improve global health care and the future of the Korea. Now we are about to leap towards the world-class institute. Our goal is to become a leading research-oriented medical college based on fundamental basic science, cutting-edge clinical research, and multidisciplinary biomedical collaboration. We will continue to hone our brilliant academic tradition accumulated by numerous outstanding graduates. I sincerely hope you to support our journey into a bright future as we continue to aim high for the world-class level. Thank you. Chan Soo Shin Dean Seoul National University College of Medicine
5
History
1885 Jejungwon
濟衆院
1899 National Medical School
醫學校
Establishment of the first medical school accreditation system in Korea
Establishment of the first modern national hospital in Korea
1946 Seoul National University College of Medicine
Foundation for Korean modern medicine Korea’s history of advancing modern medicine coincides with the history of Seoul National University College of Medicine. SNUCM was established in 1946, pursuing the philosophy of Ji Seok-yeong, Korea’s founding father of modern medicine. SNUCM produced its first graduates in 1947, thereby laying the foundation for Korea’s modern medicine. Song Chon Ji Seok-yeong, Principal of National Medical school
1899
1902
1908
HISTORY National Medical School opened / Ji Seok-young was the school’s first principal / Kim Ik-nam was the first instructor
6
First commencement ceremony of the National Medical School was held / 19 certified doctors were produced
Kim Ik-nam and other graduates of the National Medical School formed the Doctors’ Association/Parent organization of the Korean Medical Association
SEOUL NATIONAL UNIVERSITY COLLEGE OF MEDICINE Daehan Hospital Main Building (Clock Tower) 1 9 0 7
Daehan Hospital Operating Room 1 9 0 7
First Diploma of Graduation at SNUCM 1 9 4 7
SNUCM Main Building 1 9 4 6
1946
Two Seoul Medical Colleges were merged to form SNUCM
1947
First commencement ceremony of SNUCM was held
1952
SNUCM’s first six Ph.D.’s in medicine were awarded
1954-61
Minnesota Project was launched and completed
7
History
Multi-Disciplinary Laboratory opend 1 9 7 5
Kim Soo Tae, Liver transplantation 1 9 8 8
Since Seoul National University College of Medicine first opened in 1946, we set a goal to develop competent qualified doctors. As a result, we have produced extremely talented and dedicated medical professionals. Taking pride in shouldering the grave responsibility of bearing the future of Korea’s medicine with our school’s future, we are spearheading the advancement of Korea’s medicine
The first successful birth through in vitro fertilization in Korea 1 9 8 5
1963
Korea’s first successful open-heart surgery using a heart-lung machine was performed
8
1972
The Institute of Reproductive Medicine and Population opened
1974
The Medical Library was opened
1975
The MultiDisciplinary Laboratory (MDL) opened
1976
The Museum of Medicine opened
1977
World’s first hepatitis B vaccine was developed
Trailblazer for Advancing Medical Science Global medicine to Korea, Korean medicine to the World! Seoul National University College of Medicine is soaring to the top ranks of the world’s foremost medical research and educational institutions. Seoul National University College of Medicine strives to exceed its current successes, will continue to blaze new trails, and make its mark as a global leader in the field of medicine.
1978
Seoul National University Hospital (SNUH) was established as a special corporation
1984
The Liver Research Institute opened
1985
The Children’s Hospital opened
1990
The Research Building opened
1994
Korea’s first successful remote cardiac transplantation performed
1999
New dormitory building opened
9
History
SNUCM is a promise towards the future of medicine through the cultivation of world-class medical professionals.
We strive to cultivate a new generation of international health care providers with a solid educational foundation based on empathy and communication, securing a vibrant future for the health care industry.
Establishment of the Convergence Research Building 2 0 1 6
2003
A new Cancer Research Institute opened / Dr. Lee Jong-wook was elected Director-General of WHO
10
2007
Department of Biomedical Sciences was established
2008
SNU Biomedical Science Building opened
2012
Institute for Health and Unification Studies and JW LEE Center for Global Medicine opened
2013
Ji Seok-yeong Center (Clinical Training Center) and Health Quotient Center opened
SNUCM is soaring high in the world.
2018 QS World University Rankings Ranked 42nd in Medical Field (4th in Asia)
2014
Protein Metabolism Medical Research Center and Wide River Institute of Immunology established
2015
Commemoration ceremony of 116th year anniversary of the first medical school in Korea. Announcement of the new education program
2016
The 100th anniversary of Kyung Sung Medical School. The 90th anniversary of the foundation of Medical Department in Kyung Sung University. Establishment of the Convergence Research Building
11
SEOUL NATIONAL UNIVERSITY COLLEGE OF MEDICINE Our Mission Development of the finest medical scientists to tackle the problems of health care. Cultivation of leaders in the industry with the highest skills in medical research. Production of humanitarian doctors contributing toward the betterment of humanity.
12
Part. 1
Strengthening the Future of Health Care
Education and Research
Seoul National University College of Medicine
14
15
Part. 1
Education The core educational principles of SNUCM are built upon a foundation of respect for humanity.
Conducting creative scientific research
Promoting health and relieving the pain and suffering of disease Educational Goals
SNUCM aims to produce graduates with the following capabilities and qualifications Acting ethically and professionally, with a focus on service
Leading society with an international perspective
Seoul National University College of Medicine Educational Course
01
Premedical Course (2Years)
02
College of Medicine (4Years)
03
Graduate School
At SNUCM, the foundational education on medicine is reinforced by character growth, leadership skills, and altruistic principles. Through such efforts, we strive to develop the proper clinical skills in our students to correctly diagnose and treat patients, as well as developing researchers and medical scientists to fight the diseases that ail humanity. SNUCM continues to support the advancement of medical science and technology by encouraging communication and collaboration across all the various departments. We believe that this philosophy will be the engine that drives the future of the global health.
16
01
Premedical Course
The Premedical Course encourages close collaboration and integration among the Medicine, Natural Sciences, Engineering, and the Social Sciences, leading to a synergy that will help strengthen the performance of future doctors.
•Educational Principles The Premedical Course recognizes the diverse backgrounds of each student and allows a degree of freedom that will bolster responsibility and self-motivation. The students will build upon their own strengths and weaknesses, nurturing them to become independent thinkers by self-directed learning.
01
02
03
04
Encouraging self-
Expanding social and
directed learning by
human science courses
Building communal ties
between students
offering a diverse
in order to lay down a
and leadership skills
and faculty in order to
options for courses
firm foundation in ethical
through various support
encourage self-motivation
and levels.
principles for the future.
programs.
and pride.
Developing close ties
•Educational Goals and Skill Sets Goals
Skill Sets
Critical skills to understand individuals and society
•Foundational knowledge of the Arts and Culture
•Analytical grasp on Historical, Social, and Economical issues
•A respect and understanding of diversity
•Recognition and practice of social responsibilities
Comprehensive knowledge of science and technology
•Foundational Knowledge of Natural Science
•Foundational Knowledge of Biomedical Science
•Foundational Knowledge of Mathematics
•Foundational Knowledge of Engineering
Fitness and overcoming adversity
•Strengthening overall fitness
•Balancing mind and body
•Overcoming adversity through teamwork
•Self-development through cultural activity
Communication skills within an intellectual community
•Logical thinking and expressive competency
•Deductive reasoning and problem solving skills
•Understanding and involvement in knowledge creation
•Global communication skills 17
Part. 1
Eduction on humanities for comprehensive understanding of disease
Human
Society
and patients
02
College of Medicine Seoul 2016 Lee Jong-Wook Curriculum
•Human – Society – Medicine The final objective of Human – Society – Medicine is to foster the knowledge and attitude needed in order to grow as a professional health care provider. Through the curriculum, students should seek ethical and moral conscientiousness, empathy, emotional and behavioral self-control, communication skills, communal understanding, social responsibility, critical thinking and problem solving, broad insights and respect for diversity. The program is made up of six areas, which includes Understanding of Humanity, Medical Ethics, Doctors and Society, Self-Development and Leadership, preventive and Environmental Medicine, and International Healthcare. These are taught in block courses for 1- 2 weeks each semester. The main difference in curriculum with other institutions is the fusion of all six areas throughout the curriculum. In addition, discussion groups are activated to promote self- motivated learning, subleting big class lectures.
18
Medicine
•Medical Research Program
Medical Research ➊
Advanced Elective Courses
Near the end of the freshman year, a
For six-weeks during the senior year,
The Medical Research Program spans
two-week Medical Research 1 class
students are offered a wide variety of
the entire 4-years in order to strengthen
teaches students Medical Statistics,
Advanced Elective Courses with the
medical research skills.
Research Ethics, and Laboratory
purpose of widening future options and
Safety Education, so that they will
give students a chance to experience
have a firm foundational understanding
fields outside their main curriculum.
for the basic and clinical research.
Medical Research ➊
Medical Research ➋ Mentor-Mentee relationship For a ten-week period In the sophomore year, each student is matched with a professor to allow one-on-one correspondence through regular research meetings and discussions. The students are given the opportunity to work on their own research
Medical Research ➋
projects in order to gain hands-on experience. Autonomous research performance By participating in medical research, the students run through the entire process themselves, from framing hypotheses, designing research protocols, acquiring analysis skills, formulating conclusions, and writing research papers. Through this process, even
Advanced Elective Courses
students can build up fundamental ability as a scientist and leading clinician.
The Cultivation of Medical Scientists to be the Future Leaders of the Health Industry
19
Part. 1
Cultivate self-motivated education within students in clinical medicine and other fields.
03
Graduate School
•Overview Basic Medical Science Anatomy, Pathology, Microbiology and Immunology, Preventive, Parasitology and Tropical Medicine, History of Medicine & Medical Humanities, Forensic Medicine, Health Policy and Management, Biomedical Engineering, Medical Education
Department of Medicine
Clinical Science Internal Medicine, Surgery, Pediatrics, Obstetrics and Gynecology, Orthopaedic Surgery, Urology, Otorhinolaryngology-Head & Neck Surgery, Thoracic and Cardiovascular Surgery, Neurosurgery, Psychiatry, Ophthalmology, Dermatology, Radiology, Anesthesiology and Pain medicine, Plastic & Reconstructive Surgery, Radiation Oncology, Laboratory medicine, Rehabilitation medicine, Nuclear Medicine, Family Medicine, Emergency Medicine Translational Medicine
Based on 2018 Medical Majors
Physiology & Neuroscience Molecular Medicine & Oncology
Department of Biomedical Sciences
Systems Medicine, Informatics and Precision Medicine Immunology Biomedical Imaging
Department of Clinical Medicine Sciences – Interdisciplinary Programs: Cancer Biology / Clinical Pharmacology and Therapeutics / Medical Informatics / Stem-Cell Biology 20
21
Part. 1
Advanced Education for Clinician-Scientists •Basic Research Training Program for M.D. The SNUCM has been operating the Basic Research Training Program for M.D. to foster the next generation of leading medical researchers. The Program combines training in basic science and clinical medicine. SNUCM provides financial support and a guarantee of status for the trainees to stable the atmosphere for education.
Purpose of Establishment ➊ Combined training in basic science and clinical medicine
for the next generation of leading medical scientists. ➋ Stable environment for academic pursuits. ➌ Steady flow of trained medical scientists with advanced skills
in basic research, clinical application, and Industrialization through advance of biomedical science.
22
Educational Goals
Creative thinking to identify novel issues Health care professionals must be
Data analysis abilities using diverse research methodology are
able to identify and understand new
capabilities for data analysis
problems that continue to rise with the
and diverse research methodology
advancement of international
are essential to diagnose and solve
biomedical field.
new problems.
Continuous research activities and acquisition of new knowledge
Contributions towards welfare and the improvement of human health
Through continuous research and
A sense of duty must be instilled towards
the acquisition of new knowledge,
improving welfare and the overall health
medical scientists will be able to gain
of humankind to further advancements
global competitiveness.
in Biomedical Science.
23
Part. 1
Research Training future generations of medical scientists on state-of-art technology and creativity.
The ultimate goal of medical research is to identify the causes and mechanism of diseases and to develop innovative technology to prevent, diagnose, and cure diseases.
24
Main Research Centers
Research Facilities Cancer Research Institute Liver Research Institute SNU Institute on Aging Wide River Institute of Immunology Institute of Reproductive Medicine and Population Institute of Endemic Diseases Neuroscience Research Institute Institute of Medical and Biological Engineering, Medical Research Center Institute of Environmental Medicine Institute of Radiation Medicine Genomic Medicine Institute Institute of Allergy and Clinical Immunology Laboratory of Transplantation Immunology Institute of Human Behavioral Medicine Institute of Human Environment Interface Biology Institute of forensic science Sensory Organ Research Institute Institute of Health Policy and Management Kidney Research Institute Ischemic/Hypoxic Disease Institute
Core Labs Biomedical Center for Animal Resource Development Core Research Facilities Medical Research Collaborating Center Institute for Experimental Animals
Hongcheon Research Institute
Liver Research Institute
Cancer Research Institute
25
Part. 1
Research Goals
The ultimate goal of research at the SNUCM is the development of innovative fundamental technology and treatment techniques to enter clinical practice for treatment of patients. With ongoing financial support of the government and the hard work of our professors, the university is proud to be ranked the 1st in both the number of research papers published each year and the amount of research funding among medical colleges in Korea. The influence of these research outcomes outstands across the globe through various kind of contribution, helping educate students and treating patients.
Unit: Persons
2018.3.1. Standard
Researchers by status
Faculty
Student College of Medicine Students
Graduate Students
Researcher / Staff
Premedical Course Students
875
517
26
Clinical Science
412
Basic Science
105
4th Year
152
3rd Year
154
905 618
2nd Year
156
1st Year
162
2nd Year
107
1st Year
144
Masters Program
487
Staff
175
PhD Program
418
Researcher
443
2017 Annual Statistics
$ 232.1 million
Research Fund Amount
Total Research Papers Published
Top In Korea
2797
Papers published in high impact journals* * Thomson impact factor > 10.0
141
The New England Journal of Medicine The Journal of The American Medical Association Immunity Cancer Cell The
n e w e ng l a n d j o u r na l
of
m e dic i n e
original article
Tofacitinib versus Methotrexate in Rheumatoid Arthritis Eun Bong Lee, M.D., Roy Fleischmann, M.D., Stephen Hall, M.D., Bethanie Wilkinson, Ph.D., John D. Bradley, M.D., David Gruben, Ph.D., Research Tamas Koncz, M.D., Sriram Krishnaswami, Ph.D., Gene V. Wallenstein, Ph.D., Chuanbo Zang, Ph.D., Samuel H. Zwillich, M.D., and Ronald F. van Vollenhoven, M.D., Original Investigation for the ORAL Start Investigators*
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non–Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor A Meta-analysis
A bs t r ac t Background
Methotrexate is the most frequently used first-line antirheumatic drug. We report the From Seoul National University College findings of a phase 3 study of monotherapy with tofacitinib, an oral Janus kinase inhibi- of Medicine, Seoul, South Korea (E.B.L.); Metroplex Clinical Research Center, Dallas tor, as compared with methotrexate monotherapy in patients with rheumatoid arthritis (R.F.); Cabrini Health and Monash University, Melbourne, VIC, Australia (S.H.); June-Koo Lee, MD; Seokyung Hahn, PhD; Dong-Wan Kim, MD, PhD; Koung Jin Suh, MD; Bhumsuk Keam, MD; who had not previously received methotrexate or therapeutic doses of methotrexate. Groton,Lee, CT MD, (B.W., J.D.B., D.G.,Heo, S.K.,MD, PhD Tae Min Kim, MD,Pfizer, PhD; Se-Hoon PhD; Dae Seog
Methods
Immunity
G.V.W., C.Z., S.H.Z.); Pfizer, New York
Article
We randomly assigned 958 patients to receive 5 mg or 10 mg of tofacitinib twice (T.K.); and Karolinska Institute, Stockholm Supplemental content at Address reprint requests to Dr. daily or methotrexate at a dose that was incrementally increased to 20 mg perIMPORTANCE week (R.F.V.). jama.com Current at guidelines recommend both epidermal growth factor receptor (EGFR) Wilkinson Pfizer, 445 Eastern Point Rd., over 8 weeks; 956 patients received a study drug. The coprimary end points atkinase tyrosine (TKIs) andGroton, cytotoxic chemotherapy drugs as standard treatment Bldg.inhibitors 98, MS 8260-2517, CT 06340, options with wild-type (WT) EGFR who were previously treated for non–small cell month 6 were the mean change from baseline in the van der Heijde modified totalfor patients or at bethanie.wilkinson@pfizer.com. lung cancer (NSCLC). However, it is not clear that EGFR TKIs are as efficacious as Sharp score (which ranges from 0 to 448, with higher scores indicating greater * A in complete investigators in the chemotherapy patientslist withofWT EGFR. structural joint damage) and the proportion of patients with an American College ORAL Start study is provided in the Suppleof Rheumatology (ACR) 70 response (≥70% reduction in the number of both tender mentary Appendix, available at NEJM.org. OBJECTIVE To determine the association between first-generation EGFR TKI vs and swollen joints and ≥70% improvement in three of five other criteria: the pa- N Engl 2014;370:2377-86. chemotherapy andJ Med survival in advanced NSCLC patients with WT EGFR. tient’s assessment of pain, level of disability, C-reactive protein level or erythrocyte DOI: 10.1056/NEJMoa1310476 Copyright © 2014EMBASE, Massachusetts Medical Society. sedimentation rate, global assessment of disease by the patient, and global assessDATA SOURCES PubMed, Cochrane database, and meeting abstracts Sang-Uk of the Seo,1 Nobuhiko Kamada,2 Raúl Muñoz-Planillo,1 Yun-Gi Kim,1 Donghyun Kim,1 Yukiko Koizumi,1 Mizuho Hasegawa,1 Stephanie D. Himpsl,3 Hilary P. Browne,4 Trevor D. Lawley,4 Harry L.T. Mobley,3 Naohiro Inohara,1 American Society of Clinical Oncology and European Society of Medical Oncology through ment of disease by the physician).
Distinct Commensals Induce Interleukin-1b via NLRP3 Inflammasome in Inflammatory Monocytes to Promote Intestinal Inflammation in Response to Injury Cancer Cell
Article
and Gabriel Núñez1,*
December 2013.
Results
1Department
of Pathology and Comprehensive Cancer Center
2Division of Gastroenterology, Department of Internal Medicine Mean changes in the modified total Sharp score from baseline to month 6 were sigSTUDY SELECTION Eligible studies were randomized controlled trials comparing3Department EGFR TKI of Microbiology and Immunology nificantly smaller in the tofacitinib groups than in the methotrexate group, but changes with conventional chemotherapy in patients with advanced NSCLC. Out of 1947 retrieved The University of Michigan Medical School, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA were modest in all three groups (0.2 points in the 5-mg tofacitinib group and <0.1articles, point11 trials incorporating 1605 patients with WT EGFR were included. 4Bacterial Pathogenesis Laboratory, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire CB10 1SA, UK in the 10-mg tofacitinib group, as compared with 0.8 points in the methotrexate group *Correspondence: gabriel.nunez@umich.edu DATA EXTRACTION AND SYNTHESIS Two reviewers extracted trial characteristics and [P<0.001 for both comparisons]). Among the patients receiving tofacitinib, 25.5% in http://dx.doi.org/10.1016/j.immuni.2015.03.004 outcomes. the 5-mg group and 37.7% in the 10-mg group had an ACR 70 response at month 6, as The risk of bias was evaluated using the Cochrane tool. All measures were pooled using random-effects models and 95% CIs were calculated. compared with 12.0% of patients in the methotrexate group (P<0.001 for both com5,12 VOL U MYang-Soon E 34 NU M B E6RYanghee 34 DKim, EC E1 MSo B E Hee R 1 ,Nam, 2 0 116 Jinkuk Kim,1,3,12 In-Hee Lee,1,2,12 Hee Jin Cho,1,4,12 Chul-Kee Park, Jung, SUMMARY are hyporesponsive to bacterial Toll-like receptor ligands such parisons). Herpes zoster developed in 31 of 770 patients who received tofacitinibMAIN (4.0%) Byung Sup Kim,6 Mark D. Johnson,8 Doo-Sik Kong,6 Ho Jun Seol,6 Jung-Il Lee,6 Kyeung Min Joo,1,4,7 Yeup Yoon,1,4 OUTCOMES AND MEASURES The primary outcome was progression-free survival (PFS), as lipopolysaccharides (Lotz et al., 2006; Smythies et al., Woong-Yang Park,1,2,4 Jeongwu Lee,11 Peter J. Park,9,10,13,* and Do-Hyun Nam1,4,6,13,* and in 2 of 186 patients who received methotrexate (1.1%). Confirmed cases of measured cancer as hazard ratios (HRs). The secondary outcomes were objective response rate and The microbiota stimulates inflammation, but the sig- 2005). In addition, several barriers including the mucus layer 1Samsung JOURNAL OF CLINICAL ONCOLOGY Biomedical Research Institute (including three cases of lymphoma) developed in 5 patients who received tofacitinib
Spatiotemporal Evolution of the Primary Glioblastoma Genome •
overall survival, expressed as relative risks and HRs, respectively.
naling pathways and the members of the microbiota
and in 1 patient who received methotrexate. Tofacitinib was associated with increases involved remain poorly understood. We found that with microbiota induces interleukin-1b (IL-1b) release in creatinine levels and in low-density and high-density lipoprotein cholesterolRESULTS levels. Among patients with WT EGFR tumors, chemotherapy was associatedthe improvement of PFS, compared with TKI (HR for TKI, 1.41; 95% CI, 1.10-1.81). Noupon statistically intestinal injury and that this is mediated Author Affiliations: Department of significant subgroup difference was identified in terms of line of treatment (first-line vs NLRP3 inflammasome. via the Enterobacteriaceae
Conclusions
Internal Medicine, Seoul National In patients who had not previously received methotrexate or therapeutic doses ofsecondmeth-or later-line), experimental drug, dominant ethnicity, or EGFR mutationand analysis in particular University the pathobiont mirabilis, Hospital, Seoul,Proteus Republic otrexate, tofacitinib monotherapy was superior to methotrexate in reducing signs and Trials using more sensitive platforms than direct sequencing were associated method. withrobust a of Korearelease (J.-K. Lee, D.-W. Suh, comparable induced IL-1b thatKim, was Keam, T.M. Kim, S.-H. Lee, Heo); significant symptoms of rheumatoid arthritis and inhibiting the progression of structural joint PFS benefit with chemotherapy (HR for TKI, 1.84; 95% CI, 1.35-2.52).toThe that induced by the pathogen Salmonella. Upon Medical Research Collaborating association or injury, production epithelial of IL-1b in the intestine damage. The benefits of tofacitinib need to be considered in the context of the risks of of chemotherapy with improvement in PFS was also significant in secondCenter, Seoul National University later-line trials (HR, 1.34; 95% CI, 1.09-1.65). The objective response rate was higher was with largely mediated intestinal Ly6Chigh monoHospital,by Seoul, Republic of Korea adverse events. (Funded by Pfizer; ORAL Start ClinicalTrials.gov number, NCT01039688.)
(Hahn); Department of Medicine, chemotherapy (92/549, 16.8%, vs 39/540, 7.2%, for TKI; relative risk for TKI, 1.11; 95% CI, cytes, required chemokine receptor CCR2 and was Seoul National University College of 1.02-1.21); however, no statistically significant difference was observed with respect to overall abolished by deletion of IL-1b in CCR2+ blood mono2377 n engl j med 370;25 nejm.org june 19, 2014 Medicine, Seoul, Republic of Korea survival (HR for TKI, 1.08; 95% CI, 0.96-1.22). cytes. Furthermore, colonization with P. mirabilis (Hahn); Cancer Research Institute, The New England Journal of Medicine Seoul National University College of promoted intestinal inflammation upon intestinal Medicine, Seoul, Republic of Korea Downloaded from nejm.org at Seoul National University on June 21, 2018. For personal use only. No other uses without permission. CONCLUSIONS AND RELEVANCE Among patients with advanced NSCLC harboring WT EGFR, injury via the production of hemolysin, which (D.-W. Kim, Keam, T.M. Kim, S.-H. Copyright © 2014 Massachusetts Medical Society. All rights reserved. conventional chemotherapy, compared with first-generation EGFR TKI, was associated with required NLRP3 and IL-1 receptor signaling in vivo. Lee, Heo). improvement in PFS but not overall survival. Thus, upon intestinal injury, selective members of Corresponding Author: Dong-Wan
the microbiota stimulate newly recruited monocytes Kim, MD, PhD, Department of Internal Medicine, Seoul National to induce NLRP3-dependent IL-1b release, which University Hospital, 101 Daehak-ro, promotes inflammation in the intestine. Jongno-gu, Seoul 110-744, Republic of Korea (kimdw@snu.ac.kr).
JAMA. 2014;311(14):1430-1437. doi:10.1001/jama.2014.3314
INTRODUCTION
1430
jama.com
The intestine is inhabited by trillions of resident bacteria that can Copyright 2014 American Medical Association. All rights reserved. Downloaded From: by a College of Medicine of Seoul National Univ. User on 05/29/2018
provide beneficial effects to the host (Kamada et al., 2013). For example, bacterial metabolites including vitamins and shortchain fatty acids contribute to appropriate development of the host. Resident bacteria also confer resistance against pathogen infection and are critically involved in the development of lymphoid populations in the intestine (Kamada et al., 2013). Because commensal bacteria can stimulate the immune system, the host has evolved several mechanisms to prevent inappropriate activation of inflammatory responses in the intestine. For instance, the intestinal epithelium and resident macrophages 744 Immunity 42, 744–755, April 21, 2015 ª2015 Elsevier Inc.
•
O R I G I N A L
R E P O R T
and antimicrobial peptides limit the contact between microbes 2Samsung Genome Institute and the hostSamsung immuneMedical system Center, and contribute to gutKorea homeostasis Seoul 06351, 3Samsung (Kamada and Núñez, 2014). A role for the eliciting Electronics Co., Ltd., Seoul 06351, Korea Advanced Institute of microbiota Technology,inSamsung 4Department of Health Sciences and Technology, Samsung Advanced Institute for Health Science and Technology (SAIHST), Sungkyunkwan intestinal inflammation is supported by findings that chemiUniversity, Seoul 06351, Korea cally-induced and spontaneous colitis are reduced or abolished 5Department of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul 06351, Korea in antibiotic-treated mice and germ-free mice (Garrett et al., 6Department of Neurosurgery, Samsung Medical Center 2007; Hudcovic et al., 2001; Kirkland et al., 2012; Kitajima 7Department of Anatomy and Cell Biology et al., 2001; Vijay-Kumar et al., 2007). In mouse models, certain Sungkyunkwan University School of Medicine, Seoul 06351, Korea members of8 the microbiota have been linked to inflammatory reDepartment of Neurosurgery sponses and intestinal pathology. For example, Bacteroides 9Division of Genetics Sang Min Park, Young Ho Yun, Young Ae Kim, Minkyung Jo, Young-Joo Won, Joung Hwan Back, and species andBrigham members ofWomen’s the Enterobacteriaceae family including and Hospital, Boston, MA 02115, USA Eun-Sook Lee 10Department Klebsiella pneumoniae and mirabilis can promote of Proteus Biomedical Informatics, Harvardcolitis Medical School, Boston, MA 02115, USA 11Department (Bloom et al., 2011; Garrett et al.,Cell 2010). However, the signaling of Stem Biology and Regenerative Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA 12Co-first author Sang Min Park and Young Ho Yun, Seoul pathways by which resident bacteria stimulate the host immune A B S T R A C T 13Co-senior author National University College of Medicine; system to induce inflammation in vivo remain poorly understood. Joung(D.-H.N.) Hwan Back, National Health peter_park@harvard.edu (P.J.P.), nsnam@skku.edu A critical *Correspondence: step in the activation of inflammatory responses is Purpose Insurance Service, Seoul; Young Ae Kim, http://dx.doi.org/10.1016/j.ccell.2015.07.013 the recognition of microbes or endogenous molecules produced Male cancer survivors have a higher risk of cancer than the general population, which might be Minkyung Jo, Young-Joo Won, and in the setting of infection or cellular injury by host pattern-recogEun-Sook Lee, National Cancer Center, caused by an increased prevalence of obesity or susceptibility to obesity-related carcinogenesis. We nition receptors (Takeuchi and Akira, 2010). A major innate Goyang, Republic of Korea. assessed the effects of obesity before the diagnosis of a first cancer on the development of signaling pathway is the inflammasome, a multi-protein platform Published online ahead of print at SUMMARY secondary primary cancers (SPCs). that activates caspase-1 leading to the proteolytic processing of www.jco.org on October 10, 2016. pro-interleukin-1b (IL-1b) and pro-IL-18 into their mature active Methodsmultiforme (GBM) Tumor recurrence following treatment is the majorSupported causebyofNational mortality for glioblastoma Cancer Center The study population consisted of 239,615 Korean male cancer survivors between January 2003 and forms (Schroder and Tschopp, 2010). To date, four bona fide Grant 1310252 and 1532200. patients. Thus, insights on the evolutionary process atNos. recurrence are critical for improved patient care. inflammasomes have been described, of which three, the December 2010. Incident SPCs were assessed throughout follow-up until December 2011. Cox Here, we describe our genomic analyses of the initial recurrent disclosures of potentialtumor conflicts specimens from each of 38 Authors’and NLRP1, NLRP3 and NLRC4 inflammasomes, contain a member proportional hazards models were used to calculate the hazard ratios of SPCs associated with of interest are in thealterations article online at was associated with distant GBM Nod-like patients. A substantial divergence in the landscape offound driver of the intracellular receptor (NLR) family (Franchi et al., prediagnosis body mass index (BMI), which were compared with those of first cancers in all cohort www.jco.org. Author contributions are appearance of a recurrentNLRP3 tumoris from theby initial tumor, suggesting that the genomic profile of the initial tumor 2012b). Among the NLR inflammasomes, activated participants. found at the end of this article. can including mislead bacterial targetedpore-forming therapies toxins, for theATP, distally recurred tumor. In addition, in contrast to IDH1-mutated multiple stimuli Corresponding author: Eun-Sook Lee, Results gliomas, IDH1-wild-type primary et GBMs rarely developed hypermutation following temozolomide (TMZ) treatmicrobial RNA, and particulate matter (Hornung al., 2008; MD, PhD, National Research Institute, Kei Muro*,we Hyunobserved Cheol Chung, 4,799 Veena Shankaran, Geva,SPC. Daniel Catenacci, Shilpa Gupta, Joseph Paul Eder, Talia Golan, Dung T Le, 1,614,583 person-years of follow-up, patientsRavit with The ageMariathasanment, et al.,indicating 2006). In low contrast, NLRC4 activation ishypermutation risk for TMZ-induced for these tumors under After the standard regimen. National Cancer Center, 323 Ilsan-ro, Burtness, Autumn J was McRee,1.1 Chia-Chi Lin, higher Kumudu Pathiraja, Jared Kenneth Emancipator, Jonathan Juco, Minori Koshiji, standardized incidence rate of cancer Barbara in cancer survivors times than that ofLunceford, the induced by several Gram-negative pathogens by the translocaIlsandong-gu, Goyang-si, Gyeonggi-do Yung-Jue general population. We found positive linearBang* trends between prediagnosis BMI and risk of alltion of small amounts of flagellin or PrgJ-like rod proteins into
Prediagnosis Body Mass Index and Risk of Secondary Primary Cancer in Male Cancer Survivors: A Large Cohort Study
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre,ORIGINAL open-label, RESEARCH ARTICLE phase 1b trial
Exploring Coronary Circulatory Response to Stenosis and Its Association With Invasive Physiologic Indexes Using Absolute Myocardial Blood Flow and Coronary Pressure Letter
10408, Korea; e-mail: eslee@ncc.re.kr.
combined, colorectal, liver, lymphoma, biliary tract, kidney, and obesity-related SPCs. The magnithe host cytosol (Franchi et al., 2006; Miao et al., 2010). In the © 2016 by American Clinical INTRODUCTION onset. MoreSociety than of90% of GBMs present as de novo GBMs intestine, NLRC4-dependent IL-1b production is triggered by tude of the BMI-SPC risk association in Summary male cancer survivors was stronger than that for first cancers Oncology (primary GBMs), and the remainder progress from low-grade been In shown to be upregulated Salmonella in resident phagocytes, which contribute to host the general population, whereas the Background mean BMI Expression was similarofinPD-L1 both has groups. the severely obese in some patients with gastric cancer. As part of the Glioblastoma multiforme (GBM; World Health Organization0732-183X/16/3434w-4116w/$20.00 (grades I–III) gliomas (secondaryinGBMs). The current therapeu2 phase 1b KEYNOTE-012 study, we aimed assess the(1.41; safety95% and activity of the anti-PD-1 antibody pembrolizumab in defense through the recruitment of neutrophils (Franchi et al., $ 30 kg/m ), the adjusted hazard ratios for SPCs among cancertosurvivors grade IV glioma) is the most common and most aggressive brainDOI: tics for GBM serve mostly ascategory palliative(BMI measures. Despite 10.1200/JCO.2016.66.4920 patients PD-L1-positive recurrent or metastatic of the stomach or gastro-oesophageal junction. 2012a). The role of the NLRP3 inflammasome in intestinal CI, radiation, 1.15 to 1.74) were significantly higher than with those for first cancers among all cohort adenocarcinoma participants tumor (Furnari et al., 2007; Tanaka et al., 2013). GBMs can be aggressive treatment with surgery, and the alkylating (1.12; 95%always CI, 1.09 to 1.16; classified into two categories, on the basis of the history of tumor agent temozolomide (TMZ), GBM almost recurs, and Pheterogeneity , .01).
4116
© 2016 by American Society of Clinical Oncology
worldwide, with a high incidence in east Asia.1 Most cases, especially in the USA and Europe, are diagnosed at a late stage, and treatment options are mostly restricted to cytotoxic chemotherapy, which is associated with poor outcomes.2 Despite the availability of trastuzumab for
Downloaded from ascopubs.org by Seoul National University Medical Library on HER2-positive June 21, 2018 from 147.046.161.082 patients with disease and the approval of Copyright © 2018 American Society of Clinical All rights reserved. antibody ramucirumab as theOncology. anti-VEGFR2 monoclonal
a second-line therapy, there remains a need for effective treatment options for advanced gastric cancer. PD-1 is a negative co-stimulatory receptor expressed mainly on activated T cells,6 which downregulates excessive immune responses by binding to its ligands, PD-L1 and PD-L2.7,8 PD-L1 is constitutively expressed in various tissues and can also be expressed in several tumour types, including gastric cancer.6,9–12 In tumour tissues, binding of PD-1 to PD-L1 inhibits effector T-cell function, leading to suppression of the antitumour immune response and enabling neoplastic growth.6,7 3–5
Lancet Oncology
Published Online May 3, 2016 http://dx.doi.org/10.1016/ S1470-2045(16)00175-3
OPEN doi:10.1038/nature20098
Joo Myung Lee, MD, MPH, PhD Doyeon Hwang, MD Sourasky Medical Center, factor for cancer in the general population,12-15 Jonghanne Park, MD indexes, according to different anatomic and hemodynamic lesion Findings Oct 23, 2013, Maybody 5, 2014, 39 patients for response by central Tel Aviv, Israel (R Geva MD); cancer screening andFromprevious studiesto on weight and SPCwere riskenrolled. 36 were evaluable of Chicago, Chicago, Jinlong Zhang, MD severity, have not been fullyUniversity demonstrated in patients with coronary artery assessment. (22%,largely 95% CI 10–39) patients wereofjudged treatment have led to continuously increasing sur- Eight have been confined to survivors breastto have had an overall response at central review; IL, USA (D Catenacci MD); Yaliang Tong, MD disease. all responses were partial. All 39 patients were included in the safety analyses. Five (13%) patients had a total of University of Minnesota, an incancer (CRC)17; there are vival,1,2 these advances have been offset by cancer16 or colorectal Jeong-Sun Seo1,2,3,4,5*, Arang Chee rhie1,2,3 *, Junsoo Kim1,4*, Sangjin Lee1,5*, Min-Hwan Sohn1,2,3, chang-Uk Kim1,2,3, Alex Hastie6, Hae Kim, MD six grade 3 or 4 treatment-related adverse events, consisting of two cases of grade 3 fatigue, one case each of grade 3 Minneapolis, MN, USA 6 1,5 1,5 1,5 1,5 1,5 4 4 4 creased risk of secondary primary cancers (SPCs). few studies about these associations among male , Ji-Young Yun , Jihye Kim , Junho Han cao (S Gupta MD);patients Yale University,with left anterior descending METHODS: Oneofhundred Ji-In Bang, MD Kuk , Gun Hwa Park , Juhyeok Kim , Hanna ryu , Jongbum Kim , Mira roh , pemphigoid, grade 3 hypothyroidism, and grade 3 peripheral sensory neuropathy, and one case grade 4 fifteen Jeonghun baek4, Michael W. Hunkapiller7, Jonas Korlach7, Jong-Yeon Shin1,5 & changhoon Kim4 New Haven, CT, USA Many previous studies have demonstratedpneumonitis. that the cancer survivors. In deaths addition, few studies have No treatment-related occurred. Minseok Suh, MD emission artery stenosis who underwent both 13N-ammonia positron (J P Eder MD); Sheba Medical risk of developing an SPC among cancer survivors examined how obesity might contribute to inCenter, Ramat Gan, Israel Jin Chul Paeng, MD, PhD tomography and invasive physiological measurement were analyzed. might be as great as or greater than that among the creased SPC risk. Only one study, Gibson or et metastatic al,17 Interpretation In this population of patients withby recurrent PD-L1-positive gastric cancer, pembrolizumab (T Golan MD); Kimmel Cancer Gi phasing Jeong Cheon, MD, PhD provide an opportunity (Extended Data Fig. 2a). Reads were assembled and error-corrected Myocardial blood flow (MBF) measured with positron Advances emissionin genome assembly and not suggested that elevated cancer riskantitumour in survivorsactivity, of general population.3-6 SPCs could be due hadtoa manageable toxicity profi le and promising warranting further study in phase 2 and 3 trials. Center, Johns Hopkins to investigate the diploid architecture of theKoo, human genome Bon-Kwon MD, PhD and with FALCON and Quiver5 to generate 3,128 contigs with a contig Baltimore, MD, USA tomography and invasively University, measured coronary pressures were used to only the late carcinogenic effects of cancer treatment CRC compared with the general population might reveal the full range of structural variation across population N50 length of 17.9 Mb (Extended Data Table 1, Extended Data Fig. 2b (D T Le MD); Fox Chase Cancer calculate microvascular resistance and stenosis resistance. but also the influence of shared behavioral riskMerckbe&caused by an increased prevalence of obesity Funding Co. groups. Here we report the de novo assembly and haplotype phasing and Supplementary Tables 1–3). To anchor these contigs into larger Center, Philadelphia, PA, USA (B Burtness MD); University of of the Korean individual AK1 (ref. 1) using single-molecule real- scaffolds, we used next-generation mapping (NGM) from BioNano factors or increased susceptibility to carcinogenesis. rather than increased susceptibility to obesity2 Carolina Lineberger RESULTS: Withhigh-affi progressive worsening of angiographic stenosis severity, time sequencing , next-generation mapping3, microfluidics- Genomics Irys System, which produces physical maps with unique Introduction Pembrolizumab is a selective, humanised, nity North Among shared behavioral risk factors, most related tumorigenesis. However, in that study, Comprehensive Cancer Center, based linked reads4, and bacterial artificial chromosome (BAC) sequence motifs that can provide long-range structural information bothdesigned restingtoand transstenotic pressure gradient and stenosis IgG4-κ monoclonal antibody bindhyperemic to PD-1 Chapel the fiof fthsecondary most common cancer cancers studies have focused on the associationsGastric betweencancer the is number obesity-related Hill, NC, USA
www.thelancet.com/oncology Vol 17 June 2016
Downloaded from http://circ.ahajournals.org/ by guest on June 21, 2018
318 Cancer Cell 28, 318–328, September 14, 2015 ª2015 Elsevier Inc.
Journal of Clinical Oncology
Lancet Oncol 2016; 17: 717–26
Methods This study was a multicentre, open-label, phase 1b trial done at 13 cancer research centres in the USA, Israel, See Comment page 682 Conclusion Japan, South Korea, and Taiwan. We enrolled patients with PD-L1-positive recurrent or metastatic adenocarcinoma of *Contributed equally Prediagnosis obesity is a risk factor for andorindividual SPCs, andjunction. the strength of received the BMItheoverall stomach gastro-oesophageal Patients intravenous pembrolizumab at 10 mg/kg once every Cancer Center Hospital, cancer association is slightly stronger 2inweeks malefor cancer survivors than in the general population. 24 months or until progression or unacceptable toxic effects occurred. Response was assessed every 8 weeks Aichi Nagoya, Japan (K Muro MD); Significance in accordance with Response Evaluation Criteria in Solid Tumors version 1.1. The primary objectives were safety in Yonsei Cancer Center, Yonsei J Clin Oncol 34:4116-4124. © 2016 by American Society atofleast Clinical Oncology patients who received one dose of pembrolizumab and the proportion of patients achieving overall responses in University College of Medicine, Although previous sequencing studies examined the genomic landscape of GBMs and their evolution, they did not relate South Korea BACKGROUND: AlthoughSeoul, invasive physiological assessment for coronary patients who received at least one pembrolizumab dose and who either had a post-baseline scan or who discontinued genomic evolution patterns to tumor location or treatment regimens. Our integrative clinical and genomic analyses of 38 (Prof H C Chung MD); University 5,7-9 10,11 longitudinal pairs reveal that a recurrent tumor at a distant brain site from the initial tumor has a highly divergent genomic therapy because of clinical disease progression a treatment-related adverse event before the first post-baseline tobacco and alcohol useorand the risk of stenosis has become scan. a standard practice to guide treatment strategy, of Washington, Seattle, WA, profile compared with the initial tumor, suggesting that the location of recurrence should be considered whenINTRODUCTION using the The study is registered with ClinicalTrials.gov, NCT01848834, and is ongoing but no longercirculatory enrolling patients. SPCs. Although obesity is a number well-known risk USA (V Shankaran MD); Tel Avivin invasive physiological coronary response and changes genomic profile of the initial tumor to guide targeted therapies for the recurrent tumor. Our study also demonstrates that IDH1-wild-type primary GBMs have low risk for TMZ-induced hypermutation following the standard regimen. These findings Although improvements in provide critical insights for informed clinical decisions.
Nature
Articles
De novo assembly and phasing of a Korean human genome
sequencing approaches. Single-molecule sequencing coupled with and thus block the interaction between PD-1 and its (A J McRee resistance increased (P<0.001 forMD); all)National and hyperemic MBF (P<0.001) next-generation mapping generated a highly contiguous assembly, Taiwan University Hospital, ligands.13 Pembrolizumab a manageable safety resistance andhas resting microvascular (P=0.012) decreased. with aResting contig N50MBF size of 17.9 Mb and a scaffold N50 size of 44.8 Mb, profile and has shown promising antitumour activity Taipei, Taiwan (C-C Lin MD); Merck & Co, Kenilworth,resistance NJ, (P=0.383) and hyperemic microvascular (P=0.431) resolvingwere 8 chromosomal arms into single scaffolds. The de novo in several types of advanced solid tumours and USA (K Pathiraja MA, assembly, along with local assemblies and spanning long reads, 14 not changed and maintained stable. haematological malignancies. Pembrolizumab is J Lunceford PhD, Both fractional flow reserve and closesstenosis 105 and severity, extends into 72 out of 190 euchromatic gaps in K Emancipator MD, J Juco MD, instantaneous wave-freeof ratio decreased as angiographic approved in several countries for the treatment the reference genome, adding 1.03 Mb of previously intractable M Koshiji MD); and Seoul advanced melanoma andstenosis is approved in the USA and for the resistance, transstenotic gradient increased National Universitypressure College of sequence. Highand concordance between the assembly and paired-end treatment of metastatichyperemic non-small-cell cancer (all Medicine, Seoul, South Korea MBFlung decreased P<0.001). When the presence myocardial sequencesof from 62,758 BAC clones provides strong support for the that has progressed on or after platinum-containing (Prof Y-J Bang MD) robustness of the assembly. We identify 18,210 structural variants ischemia was defined by both low hyperemic MBF and low coronary chemotherapy and expresses PD-L1, as assessed with the Correspondence to: by direct comparison of the assembly with the human reference, flowkitreserve, the diagnostic of Center fractional flow reserve and Kei Muro, Aichi Cancer PD-L1 IHC 22C3 pharmDx (Dako North America, Dr accuracy Correspondence Bon-Kwon have identifying thousands of breakpoints that, to ourto: knowledge, Hospital, Nagoya 464-8681, instantaneous wave-free did not differ, regardlessnotofbeen cutoff values of ManyKoo, Carpinteria, CA, USA; approved by the US Food and ratio MD,insertions PhD, Department reported before. of the are reflected in Japan of Internal Medicine Drug Administration).13–15hyperemic MBF and coronary the transcriptome and are shared across the Asian and population. We flow reserve. kmuro@aichi-cc.jp Center, Findings from several studies support targeting of the performed haplotype phasing Cardiovascular of the assembly withSeoul short reads, National University Hospital, 101 and PD-1 pathway in gastric cancer. Preclinical data suggest long readscirculation and linked reads from whole-genome sequencing CONCLUSIONS: This study demonstrated how the coronary Daehang-ro, Chongno-gu, Seoul, with short reads from 31,719 BAC clones, thereby achieving phased that PD-L1 expression changes is signifiin cantly upregulated response to increasing coronary stenosis severity using 110-744, Korea. E-mail bkkoo@ blocks with an N50 size of 11.6 Mb. Haplotigs assembled from singlefollowing Helicobacter pylori infection and that the 13 N-ammonium positron emission tomography–derived MBF and invasively snu.ac.kr molecule real-time reads assigned to haplotypes on phased blocks resulting decrease in T-cell proliferation can be reversed measured pressure data. Currently used resting and hyperemic covered 89%pressure– of genes. The haplotigs Sourcesaccurately of Funding,characterized see page 1807the hypervariable major histocompatability complex region as well as derived invasive physiological indexes have similar patterns of relationships 717 Key Words: coronary artery demonstrating allele configuration in clinically relevant genes such to the different anatomic and hemodynamic lesion severities. disease fractional flow reserve, as CYP2D6. This work presents the most◼contiguous diploid human myocardial ◼ instantaneous wave genome assembly so far, with extensive investigation of unreported CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. free ratio myocardial ischemia and Asian-specific structural variants, and◼high-quality haplotyping Unique identifier: NCT01366404. ◼ myocardial perfusion imaging of clinically relevant alleles for precision medicine. tomography Although massively parallel ◼ positron-emission sequencing approaches have been widely used to study genomic variation, simple alignment of short © 2017 American Heart reads to a reference genome cannot be used to investigate the full Association, Inc. range of structural variation and phased diploid architecture, which are important for precision medicine. By contrast, the single-molecule real-time sequencingDOI: platform produces long reads that can Circulation. (SMRT) 2017;136:1798–1808. 10.1161/CIRCULATIONAHA.117.029911 1798 November 7, 2017 resolve repetitive structures effectively. We integrated this technology with several other sequencing approaches to construct a high-quality Korean diploid genome assembly (Extended Data Fig. 1). SMRT sequencing of the genome of a Korean individual AK1, for whom we have previously reported the annotated variations assessed with BAC clones and array comparative genomic hybridization1, was performed at 101× coverage using Pacific Biosciences (PacBio) RSII
of the genome. Two rounds of NGM at 97× and 108× coverage were performed, with the second designed to protect fragments better from breakage at fragile sites, providing improved long-range anchoring (Supplementary Table 4). The optical maps were assembled de novo into genome maps. Hybrid scaffolding of the contigs and genome maps resulted in 2,832 scaffolds with a scaffold N50 size of 44.8 Mb (Extended Data Table 1 and Extended Data Fig. 3a). Because NGMs provide orders of magnitude longer range information (Supplementary Table 4) compared to long reads from the SMRT platform (Supplementary Table 1), we relied on the genome map when there were conflicts between the two datasets. Checks for consistency between genome maps and contigs corrected potential assembly errors within 23 contigs (Extended Data Fig. 3b and Supplementary Table 5). The final assembly after polishing with Illumina reads (Extended Data Fig. 4a) is characterized by marked contiguity that has not been achieved by non-reference assemblies of the human diploid genome6-8 so far, and improves on the previous best6 N50 length by 18 Mb (Table 1). The largest 91 scaffolds, for example, cover 90% of the genome and 8 chromosomal arms are spanned by single scaffolds (Fig. 1a). The scaffolding accuracy of the AK1 assembly was assessed using paired-end sequences from AK1 BAC library1 from 62,758 BAC clones (Extended Data Fig. 1). Most (95.4%) of the uniquely aligned BAC clones were in concordance with the assembly (Extended Data Table 2), as expected since the genomic DNA originated from the same individual. From the set of BAC clones that aligned concordant with the reference genome, 99.8% also aligned concordant with the AK1 assembly, with most of the discrepancies caused by phase differences (Supplementary Table 6). The base accuracy of the assembly was assessed by Illumina short reads (72×). The read-depth distributions of the reads mapped to GRCh37, GRCh38 and AK1 show similar patterns (Extended Data Fig. 4b). The estimated base-level error rate of the assembly was less than 10−5 based on the count of single nucleotide polymorphisms (SNPs) with unexpected alleles (Extended Data Fig. 4c and Supplementary Table 7). We used the AK1 assembly to close gaps remaining in human genome reference GRCh38. Of 190 euchromatic gaps (Supplementary Table 8), 65 were closed entirely by our de novo assembly (Fig. 1b and Extended Data Fig. 5). Local realignment and reassembly, and use of spanning reads, resolved a further 40 gaps. The closed gaps were
1
Genomic Medicine Institute (GMI), Medical Research Center, Seoul National University, Seoul 110-799, South Korea. 2Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine, Seoul 110-799, South Korea. 3Department of Biomedical Sciences, Seoul National University Graduate School, Seoul 110-799, South Korea. 4Bioinformatics Institute, Macrogen Inc., Seoul 153-023, South Korea. 5Genome Institute, Macrogen Inc., Seoul 153-023, South Korea. 6BioNano Genomics, San Diego, California 92121, USA. 7Pacific Biosciences of California, Inc., Menlo Park, California 94025, USA. *These authors contributed equally to this work. 1 3 O c t O b e r 2 0 1 6 | VO L 5 3 8 | NAt U r e | 2 4 3
© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
Circulation
27
Part. 1
Campus Life Students create a lively campus culture and attractive atmosphere through the student union and student societies.
28
Extracurricular Activities CaSA
AMSA
Songchon Medical Volunteer Community
Easten Medicine Research Society
Ieaul Treatment Club (MFC) Coexist (Group) Gugu Treatment Club
Academic Soieties
Medical Volunteer Work
SNUCM supports the numerous extracurricular activities which
Sprout International Public Health Forum MD Winners
Ukkedongmu (Group)
MExIM
Seoul Undergraduate Hospice
Soundelight
Salt Society Hiking Club
Hobby
Art Club
Culture and Arts
Wine heart Theater Club PAIM PLAY Soccer Club Freeze
Tennis Club
Sports
Choir
Religion
including medical volunteer work, culture and arts, religion, academic pursuit, hobbies, and sports.
Student Council Seoul National University Student Council The student council consists of the regulatory division and legislative body, although the regulatory division is considered the main body of the student council. The regulatory division is Office, Information Office, PR Office, Culture and Welfare Office. Rights Commission. Also, the student council oversees the yearly festival week, producing various programs for campaigning, welfare services and career exploration for the students. Representatives for Each Class and Study Group Representatives for each class gather into groups and plan for the yearly events. In addition to that, the representatives are
Basketball Club
MOCA (A capella)
Yun-gun Christian Association
participate in 41 different societies in seven different fields
A special affiliated body is also underway to establish a Human Photography Club
Magic
CMF
efforts and leadership skills. Currently, students actively
divided into the Planning and Administrative Office, Financial
Arpegio Music Club
help to strengthen communal bonds and cultivate volunteering
Baseball Club Weight-lifting Club
responsible to communicate important information to the rest of the student body. Study groups allow greater learning through teamwork and cooperation. Standing Committee The Standing Committee is a legislative organization, which was completely reshaped in 2017 by the Student Council, and is now
IVF (Korean Christian Student Association)
Volleyball Club
Yun-gun Bhuddist Association
Swim Club
Catholic Bible Reading Groupl
Table Tennis Club
made up of the Student Body President, the Undergraduate School Representative, the Pre-Medical Science Representative, and the Extracurricular Union President. The Standing Committee meets each week in conference and discusses proposals to better the needs of the student body. 29
Part. 2
Joining the World Through
Connection and Expansion
Seoul National University College of Medicine
30
31
Part. 2
Lee Jong Wook – Seoul Project Seoul National University College of Medicine transfers advanced medial technology and knowledge to the world. 'Minnesota Project' in the 1950s
In the 1950s, the ‘Minnesota Project’ was a catalyst to spur the rapid development of the Seoul National University College of Medicine. Half a century later, the Lee Jong Wook – Seoul Project gives us the opportunity to pay back that debt by sharing our advancements in medical technology with developing nations.
MOU with University of Health Sciences of Lao PDR in 2011
In 2011, SNUCM and University of Health Sciences of Lao PDR signed an MOU. SNUCM invites exchange students from Laos and provides medical equipment to their home country. SNUCM is striving to meet its social responsibility by helping Laos improve its medical technology and welfare.
32
The Lee Jong Wook â&#x20AC;&#x201C; Seoul Project was created with the financial support of KOFIH (Korea Foundation for International Health). Planned to run from 2010 to 2020, the program is named after the late Lee Jong Wook, former Director-General of the WHO, famous for his lifelong dedication towards the advancement of the Third World countries health care. The locational naming scheme was inspired by the Minnesota Project. The program was started in 2009 after Korea obtained its DAC (Development Assistance Committee) membership within OECD (Organization for Economic Cooperation and Development), changing from a country which received aid to one that gave it out. This allowed us to pass on the vital financial aid that was received through the Minnesota Project to the developing nation of Laos. Starting with the first exchange student in 2011, the program will continue on into the present, boasting 68 Laos professors now trained and continuing into the future. The eighth program begins in April of 2018, ending on the ninth in 2020. In addition, SNUCM provides additional on-site advisors and consulting, as well as providing equipment, giving guest lectures, creating a long term relationship with Laos in order to lower the mortality rate and improve overall health standards.
33
Part. 2
JW LEE Center for Global Medicine Strengthening the Capacity Building
Congenital heart diseases (CHD) are treatable conditions if the diagnosis and the surgical intervention are provided in a timely manner. Nevertheless, due to the limited medical infrastructure and specialized health professionals for diagnosis and operation, many patients have been being left out from the benefit of the surgical treatment in countries where the ability of operation and patient care is limited. This situation has motivated JW LEE Center for Global Medicine (CGM) of Seoul National University College of Medicine (SNUCM) to support in aspects of both physical infrastructure and human resource training to strengthen the capacity of countries for the cardiac surgery. The project has been conducted in several countries, including Ethiopia, Uzbekistan, Nepal, Mongolia, and China for several years. We expect to see that the capacity of countries for cardiac surgery will raise enough to provide the surgical treatment to their patients without support from outside. Hence, all CHD patients should enjoy healthy lives. Under close relationship and cooperation with governments and hospitals in developing countries, SNUCM educates local medical staffs through on-site and invitational training, particularly in the field of cardiac surgery. The training in Korea gives an opportunity for local medical staffs to be exposed to cutting-edge skills and knowledge of treatment and care for patients with CHD as well as to an advanced healthcare system. On-site training at local hospitals enables Korean staffs to supervise local health professionals in diagnosing, operating, and caring for patients. Overall, this project aims at enabling medical personnels in developing countries to treat patients with CHD on their own.
34
ETHIOPIA – Tikur Anbessa Specialized Hospital(TASH)
UZBEKISTAN – Tashkent Pediatric Medical Institute
35
Part. 2
Institute for Health and Unification Studies Institute for Health and Unification Studies has tried to build healthy community in Korean peninsula through reducing healthcare gap between North and South Korea by research and education programs. Healthcare support projects and â&#x20AC;&#x2DC;Medicine and Korean Reunification Forumâ&#x20AC;&#x2122;
Preparing Inter-Korean Exchange and Cooperation and education and training program of public health manpower for unification
36
In 2008, Seoul National University Children’s Hospital and Okedongmu Children in Korea built a Pyongyang Okedongmu Children’s clinic and Pediatric Ward in Pyongyang Medical College Hospital, and provided training program for North Korean health professionals since 2009. Based on the experiences, Institute for Health and Unification Studies(IHUS) was founded in 11th of June 2012 for not only understanding healthcare gap between North and South Korea also improving public health in North Korea to prepare a unification of Korean peninsula. IHUS has focused healthcare in North Korea and healthcare in whole Korean peninsula because North and South Korea are strongly related to build a healthy society. IHUS has also focused training program of public health manpower for unification. IHUS suggested healthcare R&D between North and South Korea because North and South Korea have their own strength in public health and it can help to reduce healthcare gap between two Koreas. IHUS has provided manpower training program for citizens, practitioners, researchers, and experts on healthcare and unification. There are two kinds of manpower training programs, one is public lecture series called ‘Tong-Tong open lecture’, the other is academic program for young leaders called ‘Tong-Bo-Ri Academy’. These two training and education programs provide understanding on current health issues in North and South Korea such as One Health and Health Security topics. Currently, IHUS is preparing healthcare cooperation with China, North and South Korea by considering change of situation in Korean peninsula. Through this approach, we expect to resume a training program for North Korean health professionals in Pyongyang Medical College and academic exchanges in public health.
37
Part. 2
International Partnerships Global Activities in International Health and Medicine.
International Exchange
The faculty members at SNUCM are leaders in domestic medical advancement, as well as showing incredible prowess within the international medical academia. By establishing MOUs and sharing knowledge with various domestic and international medical schools, students and professors are given more oppurtunities in the international exchange program so that the globalisation of medical education will rise beyond spatial and temporal boundary. Unit: Persons
Status of Foreign Trainees Europe Oceania Asia Middle East North America Central America Africa
2013 2014
13
7
19
28
7
2015 2016 2017
44
7 1 49 19
43
8
12
38
17
96 22
64
2
100
1
106
14
15
2 99
23
172
2 3
16
14
210
SNUCM provides foreign students with practical training in hospitals and various knowledge exchange programs, bringing in more foreigners each year. Unit: Persons
Status of students studying abroad in the last 3 years
151
32
29
74
6
Europe Oceania Asia
10
Middle East North America
SNUCM provides international education experience for students with the student exchange program, allowing a widening of perspective needed to become global leaders.
38
Signing MOU with International Institutions
EUROPE
country
continent
country
Institution name University of Hong Kong Li Ka Shing Faculty of Medicine
Canada
McMaster University
Hong Kong
Canada
University of British Columbia
Thailand
Thammasat University Faculty of Medicine
USA
University of California, Los Angeles(UCLA) David Geffen School of Medicine
Thailand
Chulalornkorn University Faculty of Medicine
USA
University of Southern California Keck School of Medicine
Thailand
Chiang Mai University Faculty of Medicine
USA
Temple University Of The Commonwealth System of Higher Education
Thailand
Mahidol University Faculty of Medicine
USA
Johns Hopkins University Bloomberg School of Public Health
Kazakhstan
Kazakh Medicine University
USA
University of Rochester Medical Center
Kazakhstan
Al-Farabi Kazakh National University
USA
University of Nebraska Medical Center
Kazakhstan
Astana Medical University
USA
George Washington University School of Medicine and Health Sciences
China
Harbin Medical University
USA
University of South Florida Morsani College of Medicine
China
Jilin University School of Public Health
USA
University of Chicago Medicine
China
Jilin Univesity Norman Bethune College of Medicine
USA
Michigan State University
China
Yanbian University College of Medicine
USA
New York University School of Medicine
China
Shanghai Jiao Tong University School of Medicine
USA
Rutgers-The State University of New Jersey (Biomedical)
China
Peking University Health Science Center
USA
University of Utah
China
Sun Yatďź?Sen University Zhongsan School of Medicine
USA
Columbia University(in the City of New York)
China
Tianjin Medical University /Tianjin Cancer Institute
USA
University of Pennsylvania Perelman School of Medicine
China
Peking Union Medical College
USA
Western University of Health Sciences
China
Yanda Group
USA
University of Texas, MD Anderson Cancer Center
China
Capital Medical University
USA
Rutgers-Robert Wood Johnson Medical School
Japan
Kyoto Prefectural University of Meidicne
USA
University of California, Irvine School of Medicine
Japan
University of Tokushima Faculty of Medicine
USA
Emory University School of Medicine
Japan
Tokyo Medical University
Hungary
Semmelweis University Faculty of Medicine
Japan
Tokyo Medical and Dental University Faculty of Medicine
Czech Republic
Charles University 2nd Faculty of Medicine
Japan
Kyoto University Faculty and Graduate School of Medicine
England
King's College London
Japan
Nagoya University Graduate School of Medicine
England
Liverpool School of Tropical Medicine
Japan
Osaka City University Faculty of Medicine
Spain
Universidad AutĂłnoma de Madrid School of Medicine
Japan
Osaka Medical College
Swiss
University of Basel Faculty of Medicine
Japan
Fujita Health University
Russia
I.M. Sechenov First Moscow State Medical University
Japan
Jikei University School of Medicine
Germany
University Medical Center Goettingen
Indonesia
Gadjah Mada University Faculty of Medicine
Germany
Goethe University of Frankfurt Medical Faculty
Netherlands
Maastricht University Faculty of Health, Medicine and Life Sciences
Singapore
Netherlands
University Medical Center Rotterdam Erasmus MC
Vietnam
Hanoi Medical University
Vietnam
175 Military Hospital at Ho Chi Minh City
Vietnam
The University of Medicine and Pharmacy at Ho Chi Minh City
Australia/ Domestic OCEANIA
Institution name
ASIA
NORTH AMERICA
continent
SNUCM promotes international student exchange programs and researchers academic activities in its MOU-bound active cooperation with a network of prestigious medical schools in Korea and overseas and associated international organizations, thereby continuing to bolster expansion of mutual exchanges.
University of South Australia, Quality Use of Medicine and Pharmacy Research Centre, Sansom Institute/Korea Institute of Drug Safety & Risk Management
Uzbekistan Ministry of Health via Republican Research Center of Emergency Medicine National University Singapore Yong-Loo Lin School of Medicine
Myanmar
University of Medicine 1 University of Health Sciences of Lao PDR
Australia
University of Melbourne
Laos
Australia
University of New South Wales
Taiwan
Kaohsiung Medical University
Australia
University of Sydney
Taiwan
National Taiwan University College of Medicine
New Zealand
University of Queensland School of Medicine
Taiwan
National Yang-Ming University School of Medicine
New Zealand
University of Auckland
Taiwan
Taipei Medical University College of Medicine
AFRICA
Ethiopia
St. Paul Hospital - KOFIH - Seoul University Hospital
Nepal
Kathmandu University School of Medical Sciences
ETC
Overseas
The World Health Organization(WHO/WPRO)-WHO West-Pacific Division
UAE
UAE University College of Medicine & Health Sciences
UAE
Sheikh Khalifa Specialty Hospital
39
Part. 2
SEOUL NATIONAL UNIVERSITY COLLEGE OF MEDICINE INTERNATIONAL PARTNERSHIPS
HUNGARY Semmelweis University Faculty of Medicine
CZECH REPUBLIC
HONG KONG
Charles University 2nd Faculty of Medicine
University of Hong Kong Li Ka Shing Faculty of Medicine
UNITED KINGDOM
THAILAND
King's College London Liverpool School of Tropical Medicine
Thammasat University Faculty of Medicine Chulalornkorn University Faculty of Medicine Chiang Mai University Faculty of Medicine Mahidol University Faculty of Medicine
SPAIN Universidad Autónoma de Madrid School of Medicine
SWITZERLAND University of Basel Faculty of Medicine
RUSSIA I.M. Sechenov First Moscow State Medical University
GERMANY University Medical Center Goettingen Goethe University of Frankfurt Medical Faculty
NETHERLANDS Maastricht University Faculty of Health, Medicine and Life Sciences University Medical Center Rotterdam Erasmus MC
40
AUSTRALIA University of South Australia, Quality Use of Medicine and Pharmacy Research Centre, Sansom Institute/한국의약품안전관리원 University of Melbourne University of New South Wales University of Sydney
NEW ZEALAND University of Queensland School of Medicine University of Auckland
ETHIOPIA St. Paul Hospital - KOFIH - Seoul University Hospital
KAZAKHSTAN Kazakh Medicine University Al-Farabi Kazakh National University Astana Medical University
CHINA Harbin Medical University Jilin University School of Public Health Jilin Univesity Norman Bethune College of Medicine Yanbian University College of Medicine Shanghai Jiao Tong University School of Medicine Peking University Health Science Center Sun Yat－Sen University Zhongsan School of Medicine Tianjin Medical University /Tianjin Cancer Institute Peking Union Medical College Yanda Group Capital Medical University
JAPAN
MYANMAR University of Medicine 1
LAO PDR University of Health Sciences of Lao PDR
TAIWAN Kaohsiung Medical University National Taiwan University College of Medicine National Yang-Ming University School of Medicine Taipei Medical University College of Medicine
NEPAL
Kyoto Prefectural University of Meidicne University of Tokushima Faculty of Medicine Tokyo Medical University Tokyo Medical and Dental University Faculty of Medicine Kyoto University Faculty and Graduate School of Medicine Nagoya University Graduate School of Medicine Osaka City University Faculty of Medicine Osaka Medical College Fujita Health University Jikei University School of Medicine
INDONESIA Gadjah Mada University Faculty of Medicine
UZBEKISTAN Ministry of Health via Republican Research Center of Emergency Medicine
SINGAPORE National University Singapore Yong-Loo Lin School of Medicine
Kathmandu University School of Medical Sciences
UNITED ARAB EMIRATES UAE University College of Medicine & Health Sciences Sheikh Khalifa Specialty Hospital
VIETNAM Hanoi Medical University 175 Military Hospital at Ho Chi Minh City The University of Medicine and Pharmacy at Ho Chi Minh City
CANADA McMaster University University of British Columbia
University of California, Los Angeles(UCLA) David Geffen School of Medicine University of Southern California Keck School of Medicine Temple University Of The Commonwealth System of Higher Education Johns Hopkins University Bloomberg School of Public Health University of Rochester Medical Center University of Nebraska Medical Center George Washington University School of Medicine and Health Sciences University of South Florida Morsani College of Medicine University of Chicago Medicine Michigan State University New York University School of Medicine Rutgers-The State University of New Jersey (Biomedical) University of Utah Columbia University(in the City of New York) University of Pennsylvania Perelman School of Medicine Western University of Health Sciences University of Texas, MD Anderson Cancer Center Rutgers-Robert Wood Johnson Medical School University of California, Irvine School of Medicine Emory University School of Medicine
ETC. The World Health Organization(WHO/WPRO)-WHO West-Pacific Division
41
Part. 2
Leaders in Society
Proud Alumni of Seoul National University College of Medicine The alumni of SNUCM have left deep footprints in our society as well as the history of mankind. Being the first ever medical institute in Korea, SNUCM is proud to have nurtured the very finest leaders in education, research and treatment.
the late
Lee Jong Wook•
23rd Graduating Class 1969
In 1983, Lee Jong Wook began working at the WHO as a director of leprosy elimination in the South-Pacific. He led the efforts of reducing the world’s polio
Shin Young Soo•
patients down to 1 in 10,000, and got the nickname ‘King of Vaccine'. He was
23rd Graduating Class 1969
appointed a Director-General of the WHO
Served as a Professor of Health Policy and
in 2003. He was called "Schweizer of Asia"
Management at SNUCM. He worked as a
due to his noble spirit, and was named "The
Served diverse positions of education
President of the Health Insurance Review
100 Most Influential People in the World"
and health politics, such as Professor of
and Assessment Service of Korea. He was
by Time magazine in 2004.
Preventive Medicine at SNUCM, Dean
elected as the head of the World Health
of SNUCM, President of Seoul National
Organization's Western Pacific Region
University, and President of Korea National
(WHO/WPRO), who is in charge of
University of Education. He was also deeply
health and welfare of approximately 1.8
Kwon Lee Hyuk• 1st Graduating Class 1948
Major Positions • Director of Center for Disease Prevention and Control, WHO/WPRO
involved in the government affairs as a
billion people, or about 30% of the world's
• Director of Vaccine Safety, WHO
Minister of Education, Health and Welfare,
population.
• 6th Director-General of WHO
• Director of Tuberculosis, WHO
and Environment. Major Positions Major Positions
42
• Honorary President of Dong-A Socio Holdings
• 10th~12th Dean of SNUCM
• President of Korea Pharmaceutical Manufacturers Association
• 2nd President of Seoul National University Hospital
• Germany First Cross Merit awardee
• 15th President of Seoul National University
• Chairman of Sangju High School Foundation
• 26th Minister of Education
• Foundational President of the 16th Korean Youth Association
Leaders in Medicine
the late
Kim Chung Yong•
13th Graduating Class 1959
In the late 1960s, the major cause of chronic liver disease in Korea was hepatitis B virus infection. In 1973, he succeeded in isolating the hepatitis B virus antigen from
Lee Ho Wang•
the serum. Then, he developed the safest and most effective vaccine against hepatitis
8th Graduating Class 1954
B, cirrhosis and primary hepatocellular
Leading medical scientist and microbiologist
carcinoma associated with hepatitis B virus.
in Korea. He discovered the 'Hantan Virus'
His broad contribution to public health by
and 'Seoul Virus', which are epidemic
significant reduction of hepatitis prevalence
hemorrhagic fever pathogens, for the first
in Korea, gave him a nickname 'Liver
In 1980, he volunteered at the National
time in the world and contributed to human
Doctor'.
Sorokdo Hospital, and started to take care of
Kim In Kwon• 29th Graduating Class 1975
health welfare by developing preventive
the leprosy patients. In 1983, he gave
vaccine and diagnosis method.
up all his profits and started to work for
He is also the first Korean member of the
Major Positions
rehabilitation and human rights for the
American Academy of Arts and Science,
• President of Korean Society of Internal Medicine
underprivileged at Yeosu Aeyang Hospital.
• President of Korea Research Foundation
Since the mid-1990s, he continued his
and the honorary member of the Japan Academy.
• Korea Science Award • National Medal of the Mugunghwa
service for the neglected class of people whoc is suffering from arthritis.
Major Positions • US Best Citizen's Merit • Awardee of Inchon Prize, Science Prize, Ho-Am Prize
Major Positions
• Prince Mahidal Award of Thailand
• Awarded the 2nd Jang Kiryu Award
• Changjojang Medal for Excellence in Science and Technology
• National Medal of the Mugunghwa
• Induction to Korean Science and Technology Hall of Fame
• 4th Sungchun Award
• Korean Science and Technology Man of Merit
• Honorary Director of Yeosu Aeyang Hospital
43
Part. 2
Training Hospitals
Six centers for efficient research and training 01
h tt p : / / w w w. s n u h . o r g
02
h tt p : / / w w w. s n u b h . o r g
03
h tt p : / / w w w. b r m h . o r g
04
h tt p : / / w w w. s n u h . o r g / ch i l d /
05
h tt p : / / c a n c e r. s n u h . o r g
06
h tt p : / / h e a l t h c a r e . s n u h . o r g
44
01
02
03
Seoul National University Hospital
SNU Bundang Hospital
As Korea’s leading hospital,
SNU Bundang Hospital is equipped with
SNUH is endeavoring to raise Korean
cutting-edge digital facilities and systems,
Seoul Metropolitan Government-SNU Boramae Medical Center
medicine to the global standard.
providing preeminent medical services
SMG-SNU Boramae Medical Center
for patients.
provides reliable, high-quality medical
•Ranked first in the Korea Brand Power Index for 18 consecutive years •Ranked first in the National Brand Competitiveness Index
•Korea’s first EMR (Electronic Medical Record) Hospital •First to be awarded the “Beautiful Hospital” prize
•The first university hospital to earn
service to all Seoul citizens. •2018 Best medical institution for stroke treatment •The first metropolitan/provincial public hospital to be certified by the Ministry of Health and Welfare
Healthcare Organization accreditation from the Ministry of Health and Welfare
04
05
06
SNU Children’s Hospital
SNU Cancer Hospital
SNU Children’s Hospital opened up
With state-of-the-art medical
SNU Hospital Healthcare System Gangnam Center
new frontiers for treatment and cures for
facilities and relentless research,
With its outstanding medical staffs and
children’s diseases.
SNU Cancer Hospital is
superior facilities, SNU Hospital Healthcare
moving closer to curing cancer.
System Gangnam Center is providing
•Opened in 1985, Korea’s first hospital specializing in children
•Opened in 2011 •28 Professional Centers
unrivalled medical service. •Ranked first in the Korea Brand Power(Healthcare System) Index for 5 consecutive years •2010 Grand Prize of Medical Korea Awards
45
Pro d u c e d by STO RYM A KER CO M PA N Y
From the finest
www. s to r y ma ke r- c o mp a ny. c o m
Medical University in Korea To leading international medical research center
SE O U L N AT IO N A L U N IV E R SIT Y C O LLE G E O F M E D IC IN E
SNUCM 03080 103, Daehak-ro, Jongno-gu, Seoul, Republic of Korea TEL. 02–740–8114
FAX. 02–740–8190 http://medicine.snu.ac.kr